SecuritySRT / Star Tek, Inc. (85569C107)
Institutional Owners52
Institutional Shares12,920,371 - 79.76%
Common Shares Outstanding16,199,122 shares (as of 2017-12-31)
Institutional Value$ 81,836,000 USD

Institutional Stock Ownership and Shareholders

SRT / Star Tek, Inc. Institutional Ownership

Star Tek, Inc. (NYSE:SRT) has 52 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 12,920,371 shares. Largest shareholders include Csp Alpha Holdings Parent Pte Ltd, Gottlieb Daniel M, Lebowitz Steven D, Renaissance Technologies LLC, Dimensional Fund Advisors Lp, BlackRock Inc., Heartland Advisors Inc, Engine Capital Management, LLC, Vanguard Group Inc, and Price T Rowe Associates Inc /md/.
Star Tek, Inc. (NYSE:SRT) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

Embed this chart! (it updates automatically)
<a href="https://fintel.io/so/us/srt"><img src="https://images.fintel.io/us-srt-so.png" alt="SRT / Star Tek, Inc. Institutional Ownership"><a>

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2018-05-15 13F-HR MANUFACTURERS LIFE INSURANCE COMPANY, THE 2,756 686 -75.11 28 7 -75.00
2018-05-15 13F-HR Ancora Advisors, LLC 220,634 223,436 1.27 2,200 2,185 -0.68
2018-05-10 13F-HR JP Morgan Chase & Co 2,227 2,049 -7.99 22 20 -9.09
2018-05-15 13F-HR Tower Research Capital LLC (TRC) 15,036 12,811 -14.80 150 125 -16.67
2018-05-11 13F-HR Cutler Group LP Call 2,600 0 -100.00 1 0 -100.00
2018-05-04 13F-HR MCKINLEY CAPITAL MANAGEMENT LLC /DELAWARE 73,811 0 -100.00 736 0 -100.00
2018-05-14 13F-HR CADENCE CAPITAL MANAGEMENT LLC 62,231 0 -100.00 620 0 -100.00
2018-05-08 13F-HR O'SHAUGHNESSY ASSET MANAGEMENT, LLC 31,664 18,248 -42.37 316 178 -43.67
2018-05-14 13F-HR PRICE T ROWE ASSOCIATES INC /MD/ 570,293 290,590 -49.05 5,686 2,842 -50.02
2018-02-14 13F-HR SPRINGBOK CAPITAL MANAGEMENT, LLC 623 0 -100.00 7 0 -100.00
2018-05-21 13F-HR/A EAM Investors, LLC 183,761 0 -100.00 2,159 0 -100.00
2018-02-01 13F-HR ALGERT GLOBAL LLC 158,066 0 -100.00 1,857 0 -100.00
2018-05-11 13F-HR Cutler Group LP 2,319 2,150 -7.29 23 21 -8.70
2018-05-15 13F-HR VANGUARD GROUP INC 456,935 495,519 8.44 4,556 4,846 6.37
2018-05-14 13F-HR Allianz Asset Management AG 20,007 0 -100.00 199 0 -100.00
2018-05-15 13F-HR Parallax Volatility Advisers, L.P. 1,512 0 -100.00 15 0 -100.00
2018-05-04 13F-HR Ariel Capital Advisors, LLC 43 0
2018-05-15 13F-HR Engine Capital Management, LLC 569,903 569,903 0.00 5,682 5,574 -1.90
2018-02-02 13F-HR AMERICAN CENTURY COMPANIES INC 22,335 0 -100.00 262 0 -100.00
2018-05-15 13F-HR UBS Group AG 478 0 -100.00 5 0 -100.00
2018-05-14 13F-HR TEACHERS ADVISORS INC 23,277 23,277 0.00 232 228 -1.72
2018-02-09 13F-HR Dynamic Technology Lab Private Ltd 10,300 0 -100.00 121 0 -100.00
2018-04-19 13F-HR VALLEY NATIONAL ADVISERS INC 50 50 0.00 0 0
2018-05-15 13F-HR CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM 16,100 16,100 0.00 161 157 -2.48
2018-02-14 13F-HR BALYASNY ASSET MANAGEMENT LLC 11,513 0 -100.00 135 0 -100.00
2018-04-13 13F-HR BANK OF MONTREAL /CAN/ 3,044 3,044 0.00 30 30 0.00
2018-05-07 13F-HR SCHWAB CHARLES INVESTMENT MANAGEMENT INC 21,000 21,000 0.00 210 206 -1.90
2018-05-15 13F-HR DEUTSCHE BANK AG\ 23,106 47,115 103.91 228 460 101.75
2018-05-10 13F-HR HEARTLAND ADVISORS INC 895,000 786,663 -12.10 8,923 7,694 -13.77
2018-05-15 13F-HR BANK OF AMERICA CORP /DE/ 9,071 9,443 4.10 91 92 1.10
2018-01-31 13F-HR Cypress Capital Management LLC (WY) 750 0 -100.00 9 0 -100.00
2018-05-14 13F-HR Connor, Clark & Lunn Investment Management Ltd. 12,250 0 -100.00 122 0 -100.00
2018-05-14 13F-HR Axa 27,047 0 -100.00 270 0 -100.00
2018-05-11 13F-HR BNP PARIBAS ARBITRAGE, SA 2,258 2,297 1.73 22,512 22,465 -0.21
2018-05-10 13F-HR CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM 60,391 60,391 0.00 602 591 -1.83
2018-02-14 13F-HR CORNERSTONE CAPITAL MANAGEMENT HOLDINGS LLC. 38,700 0 -100.00 454 0 -100.00
2018-05-11 13F-HR GSA CAPITAL PARTNERS LLP 10,970 0 -100.00 109 0 -100.00
2018-05-18 13F-HR/A ROYAL BANK OF CANADA 71 63 -11.27 1 1 0.00
2018-05-14 13F-HR TIAA CREF INVESTMENT MANAGEMENT LLC 53,438 28,638 -46.41 533 280 -47.47
2018-05-11 13F-HR Cutler Group LP Put 1,700 0 -100.00 2 0 -100.00
2018-03-23 SC 13D Csp Alpha Holdings Parent Pte Ltd 4,840,717
2018-05-14 13F-HR ARROWSTREET CAPITAL, LIMITED PARTNERSHIP 141,725 131,718 -7.06 1,413 1,288 -8.85
2018-05-15 13F-HR BRIDGEWAY CAPITAL MANAGEMENT INC 128,100 103,700 -19.05 1,277 1,014 -20.60
2018-05-09 13F-HR NORTHERN TRUST CORP 130,396 131,793 1.07 1,300 1,289 -0.85
2018-05-14 13F-HR MORGAN STANLEY 22,162 29,937 35.08 221 293 32.58
2018-04-24 SC 13G Gottlieb Daniel M 1,028,037
2018-05-16 13F-HR/A GROUP ONE TRADING, L.P. 0 1,170 0 11
2018-05-15 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP Call 22,400 26,200 16.96 223 256 14.80
2018-04-27 13F-HR LOS ANGELES CAPITAL MANAGEMENT & EQUITY RESEARCH INC 18,584 0 -100.00 185 0 -100.00
2018-05-03 13F-HR MEEDER ASSET MANAGEMENT INC 219 0 -100.00 2 0 -100.00
2018-02-07 13F-HR OPPENHEIMER ASSET MANAGEMENT INC. 1,411 0 -100.00 17 0 -100.00
2018-05-14 13F-HR Renaissance Technologies LLC 761,900 850,200 11.59 7,596 8,315 9.47
2018-02-14 13F-HR MACQUARIE GROUP LTD 6,571 0 -100.00 77 0 -100.00
2018-05-15 13F-HR BARCLAYS PLC 2,044 2,479 21.28 20 24 20.00
2018-05-17 13F-HR Legal & General Group Plc 1,462 1,462 0.00 15 14 -6.67
2018-02-13 13F-HR ClariVest Asset Management LLC 22,802 0 -100.00 268 0 -100.00
2018-05-15 13F-HR Ameritas Investment Partners, Inc. 892 892 0.00 9 9 0.00
2018-05-15 13F-HR GOLDMAN SACHS GROUP INC 0 20,126 0 197
2018-05-15 13F-HR STATE STREET CORP 134,384 147,043 9.42 1,342 1,438 7.15
2018-05-07 13F-HR AMERICAN INTERNATIONAL GROUP INC 6,951 6,596 -5.11 69 65 -5.80
2018-05-15 13F-HR PEAK6 Investments, L.P. 14,039 18,467 31.54 140 181 29.29
2018-05-15 13F-HR Invesco Ltd. 39,433 37,578 -4.70 394 367 -6.85
2018-02-15 SC 13G LEBOWITZ STEVEN D 978,500
2018-05-11 13F-HR DIMENSIONAL FUND ADVISORS LP 921,475 838,750 -8.98 9,187 8,203 -10.71
2018-04-12 13F-HR ACADIAN ASSET MANAGEMENT LLC 89,477 0 -100.00 893 0 -100.00
2018-05-02 13F-HR WELLS FARGO & COMPANY/MN 35,468 23,924 -32.55 353 234 -33.71
2018-05-10 13F-HR Municipal Employees' Retirement System of Michigan 44,140 44,140 0.00 440 432 -1.82
2018-05-15 13F-HR Bank of New York Mellon Corp 80,164 82,459 2.86 799 807 1.00
2018-05-11 13F-HR CITIGROUP INC 7,335 3,621 -50.63 73 35 -52.05
2018-02-09 13F-HR Virtu Financial LLC 13,318 0 -100.00 156 0 -100.00
2018-05-08 13F-HR US BANCORP \DE\ 45 0 -100.00 0 0
2018-05-10 13F-HR NEW YORK STATE COMMON RETIREMENT FUND 10,900 10,900 0.00 109 107 -1.83
2018-02-06 13F-HR Russell Investments Group, Ltd. 37,695 0 -100.00 443 0 -100.00
2018-05-10 13F-HR BESSEMER GROUP INC 17,300 7,100 -58.96 172 69 -59.88
2018-05-15 13F-HR RBF Capital, LLC 49,423 49,423 0.00 493 483 -2.03
2018-02-01 13F-HR Nationwide Fund Advisors 5,855 0 -100.00 69 0 -100.00
2018-04-20 13F-HR Seacrest Wealth Management, Llc 150 1
2018-05-15 13F-HR GEODE CAPITAL MANAGEMENT, LLC 81,309 83,130 2.24 810 813 0.37
2018-05-09 13F-HR BlackRock Inc. 816,533 812,937 -0.44 8,142 7,950 -2.36
2018-05-11 13F-HR MARTINGALE ASSET MANAGEMENT L P 44,506 19,906 -55.27 444 195 -56.08
2018-05-03 13F-HR SG Americas Securities, LLC 14,834 0 -100.00 148 0 -100.00

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

Related News Stories

Startek's Relentless Pursuit Of Optimal Operating Performance: Time To Reload On Shares

2017-11-30 seekingalpha
As I expected, Startek saw tough Q3’17 results, as the bulk of the low-margin business eliminated impacted revenue. Marked improvement seen as a client's transition to Domestic from Offshore advances. (1-1)

CUSIP: 85569C107